Total drug treatment and comorbidity in myasthenia gravis: A population-based cohort study

European Journal of Neurology

Volumn 21, Issue 7, 2014, Pages 948-955

  Andersen, J B ^a   Owe, J F ^b   Engeland, A ^a,c   Gilhus, N E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Comorbidity; Drug therapy; Myasthenia gravis

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; IMMUNOMODULATING AGENT; INSULIN DERIVATIVE; PYRIDOSTIGMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOTHERAPY; INFANT; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NORWAY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RECIPIENT; VERY ELDERLY; COHORT ANALYSIS; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COHORT STUDIES; COMORBIDITY; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NORWAY; PYRIDOSTIGMINE BROMIDE; YOUNG ADULT;

EID: 84902267282     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12439     Document Type: Article

References (23)

1. Querol L, Illa I. Myasthenia gravis and the neuromuscular junction. Curr Opin Neurol 2013; 26: 459-465.
2. Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry 2006; 77: 203-207.
3. Gilhus NE, Owe JF, Hoff JM, et al. Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis 2011; 2011: 847393.
4. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health Guidelines for ATC classification and DDD assignment. Oslo, Norway, 2005.
5. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902.
6. Mygland A, Aarli JA, Hofstad H, Gilhus NE. Heart muscle antibodies in myasthenia gravis. Autoimmunity 1991; 10: 263-267.
7. Owe JF, Skulstad Davidsen E, Eide GE, Gerdts E, Gilhus NE. Left ventricular long-axis function in myasthenia gravis. J Neurol 2008; 255: 1777-1784.
8. Mao ZF, Yang LX, Mo XA, et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci 2011; 121: 121-129.
9. Toth C, McDonald D, Oger J, Brownell K. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand 2006; 114: 124-132.
10. Ybarra MI, Kummer A, Frota ER, et al. Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr 2011; 69: 176-179.
11. Lundeen J, Fisher J, Kothari MJ. Frequency of anxiety in myasthenia gravis. J Clin Neuromuscul Dis 2004; 6: 9-12.
12. Martinez De Lapiscina EH, Aguirre ME, Blanco TA, Pascual IJ. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve 2012; 46: 174-180.
13. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007; 21: 473-481.
14. Romi F, Gilhus NE, Varhaug JE, et al. Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis. Ann N Y Acad Sci 2003; 998: 481-490.
15. Hellmann MA, Mosberg-Galili R, Steiner I. Myasthenia gravis in the elderly. J Neurol Sci 2013; 325: 1-5.
16. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007; 14: 38-43.
17. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 2005; 12: 413-418.
18. Norwegian Institute of Public Health. Norwegian Prescription Database 2007-2011. Oslo, Norway, 2012.
19. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Identifying patients with myasthenia for epidemiological research by linkage of automated registers. Neuroepidemiology 2011; 37: 120-128.
20. Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010; 17: 1445-1450.
21. Gattellari M, Goumas C, Worthington JM. A national epidemiological study of myasthenia gravis in Australia. Eur J Neurol 2012; 19: 1413-1420.
22. Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand 2014; 129 (Suppl. 198): 26-31.
23. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10: 1098-1107.